Nelli Bejanyan, Ramon V. Tiu, Azra Raza, Ania Jankowska, Matt Kalaycio, Anjali Advani, Josephine Chan, Yogen Saunthararajah, Lindsey Mooney, Jaroslaw P. Maciejewski and Mikkael A. Sekeres A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) Cancer 118
Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26741
The thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) regimen yields clinical responses in patients with primary myelofibrosis and myelodysplastic/myeloproliferative neoplasms. It is reasonable to incorporate multiple novel agents in these rare diseases.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.